Please assess the completion status of the following clinical trial:

Trial Title: Lofexidine for Inpatient Opiate Detox in Singapore

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who meet the DSM-IV criteria for a diagnosis of opiate dependence (as diagnosed by a NAMS psychiatrist).~2. Individuals are voluntarily undergoing inpatient opiate withdrawal treatment at the National Addictions Management Service (NAMS).~3. Agreeable to participating in the clinical trial and will provide written consent.~4. Males or females who are between the ages of 21-55 years. The lower limit of 21 years is in place because of lack of data on younger populations. The upper limit is set at 55 years as the likelihood of having co-morbid physical health problems is greater.~5. Individuals who have a positive urine screen for the presence of opiates (routinely given on first visit to outpatient clinic).~Exclusion Criteria:~1. Are investigator site personnel directly affiliated with this study and their immediate families, immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.~2. Are currently enrolled in, or discontinued within the last 30 days from another clinical trial or medical research judged not to be scientifically or medically compatible with this study.~3. A history of allergy/sensitivity to clonidine, lofexidine, imidazole derivatives (e.g. clotrimazole, antifungal) or alpha-2-adrenergic medications.~4. Co-dependency on alcohol, benzodiazepines or any other drug that would require detoxification.~5. A history of major physical illness (cardiovascular disease, cerebrovascular disease, renal impairment, liver disease, epilepsy, symptomatic HIV, Hepatitis B and/or C).~6. Patients with major psychiatric illness (e.g. psychotic disorders, major depression).~7. Patients prescribed analgesic\*(\*: Opioid analgesic and similar narcotic analgesics), antihypertensive, antiarrhythmic, or antiretroviral medication.~8. Baseline BP \> 140/90 mmHg or \< 85/55mmHg, and/or baseline PR \<55beats/min.~9. Significant abnormal finding from blood tests (FBC, LFT, Renal function) and ECG during screening.~10. Pregnant or breast feeding.~11. Patients are receiving and not willing to stop the drugs which may cause prolong QT interval and hypotension while using concomitant with Lofexidine, e.g. thioridazine, chlorpromazine, tricyclic antidepressants.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lofexidine & Diazepam Placebo (Type: EXPERIMENTAL): Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm.
- Diazepam & Lofexidine Placebo (Type: ACTIVE_COMPARATOR): The initial dosage of Diazepam is 10 mg per day on Day 1\&2, the dosage will be increased to 15 mg per day on Day 3\&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6\&7, 2mg per day on Day 8\&9\&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).